Chronic Myelogenous Leukemia

NOD/SCID Mice Provide In Vivo Model

Published in Blood Weekly, October 5th, 1998

The use of non-obese diabetic mice with severe immunodeficiency disease is an appropriate in vivo model of chronic myelogenous leukemia biology, researchers concluded.

After a chronic phase (CP), chronic myelogenous leukemia (CML) finally progresses to an accelerated phase (AP), and later to a blastic phase (BP) that results in death of the patient.

In vitro studies have provided little consensus on the kinetic abnormality underlying the myeloid expansion of CML, a neoplastic disorder that originates in a primitive hematopoietic stem cell. The transplantation of human CML cells into non-obese diabetic mice with severe immunodeficiency disease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry